Professor, Medicine, UCSD School of Medicine
Infectious Disease
Dr. Constance A. Benson, MD
|
|
Give Review
Constance Benson practices Infectious Disease. She researched medicine at The Ohio State University College of Medicine. Constance Benson is a published doctor as well. She has 31 publications published. The latest was: Three months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis infection in HIV co-infected persons. She accepts Medicare.
Publications
- Linezolid for Treating Tuberculosis: A Delicate Balancing Act.
- A Cross-sectional Serological Study of Cysticercosis, Schistosomiasis, Toxocariasis and Echinococcosis in HIV-1 Infected People in Beira, Mozambique.
- HIV Prevention in Clinical Care Settings: 2014 Recommendations of the International Antiviral Society-USA Panel.
- Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society-USA Panel.
- Antiretroviral Therapy and Efficacy after Virologic Failure on First-line Boosted Protease Inhibitor Regimens.
- A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with ...
- Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents--Updated Guidelines from CDC, NIH, and HIVMA of the IDSA.
- Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.
- Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE: Timing, Severity and Implications for HIV-TB programs.
- The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.
- Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study.
- Effect of Statin Therapy in Reducing the Risk of Serious Non-AIDS-Defining Events and Nonaccidental Death.
- Drug-resistant virus has reduced ability to induce immune activation.
- Performance evaluation of the MBio Diagnostics point-of-care CD4 counter.
- Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized tria...
- Tuberculosis due to Mycobacterium bovis in patients coinfected with human immunodeficiency virus.
- Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials s...
- Late presentation for human immunodeficiency virus care in the United States and Canada.
- Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.
- Effect of early versus deferred antiretroviral therapy for HIV on survival.
- AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.
- Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly act...
- Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
- Cross-sectional study of endothelial function in HIV-infected patients in Brazil.
- Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.
- Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels.
- Structured treatment interruptions--new findings.
- Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type...
- The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
- Three months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis infection in HIV co-infected persons.
Schools
Ohio State University College of Medicine
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Rush University Medical Center -
The Ohio State University College of Medicine
Hospital
-
UC San Diego Health
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871541664 |
| Last Name Of The Provider | BENSON |
| First Name Of The Provider | CONSTANCE |
| View All |
Similar Doctors
|
|
Dr. Jane C. Burns, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Oliver J. Biederman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vi Q. Bowman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua J. Minuto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel A. Bozzette, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dale K. Lieu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David T. Pride, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott L. Letendre, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Elaine F. Pierce, MD
This Doctor is OpenDoctor Recommended.
|